Retroviral-mediated IL-12 gene therapy for advanced murine tumors.
- Author:
Seon Hee KIM
1
;
Chung Sun AN
;
Hideaki TAHARA
;
Chae Hwa PARK
;
Michael T LOTZE
;
Paul D ROBBINS
;
Sun Young KIM
Author Information
1. SEOUL NATL UNIV, INST MOL BIOL & GENET, SEOUL 151742, SOUTH KOREA.
- Publication Type:Original Article
- Keywords:
interleukin-12;
cancer;
gene therapy
- MeSH:
Animals;
Breast Neoplasms;
Fibroblasts;
Genetic Therapy*;
Interleukin-12*;
Retroviridae
- From:Experimental & Molecular Medicine
1997;29(1):53-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
Interleukin 12 (IL-12), a heterodimeric cytokine, promotes an effective antitumor response against tumors of various histological types when delivered systemically as a protein or locally by gene transfer. We investigated parameters that influenced the effectiveness of IL-12 retroviral-mediated gene therapy of cancer in animals using the murine breast cancer line TS/A. Syngeneic fibroblasts (TIB80), stably transduced with a retrovirus expressing murine IL-12, were used for peritumoral injection. Injection of fibroblasts into established tumors resulted in complete regression of tumor in 40 % of animals in a dose dependent manner when treated on day 4, and 20 % when treated on day 8. Significant inhibition of growth of day 21 and day 40 tumors was observed following peritumoral injection of IL-12-expressing fibroblasts in a dose-dependent manner. Delivery of IL-12 by syngeneic fibroblasts at a tumor site is effective in eradicating established, weakly immunogenic TS/A tumors.
